i iM,«,iSfcttt)

ft 19 p-

/ G|G|G};9O yu

SLLLU c-05,1

- o

n p=>

,3,0 - -t, c-syn,Lc-tLM,tantia

vi

nan. U'OO

en.

r. vweBn«Jijqjnfi'M

v nnWlUVl^jfl vi HP!

VI HR

bet:bb

v rmvi HP! osfels.b/T ©s^en

cnoeno S-5VnfllJ

sic*;

b.

ay. nnviu^i(ay.

^nmiwT3^a€\i

©>.snatnuviynuna

en piiEJiti,a^3i<5aTHi'3Vii-3i3i!tsa?i

WTUYIfJfl VI

vil odJsb.ctyi tod: cno

vi nn OS:©GTI/Tbb a-nuvi mos: s^iuvi fed

v

l VI HP! W7UV1

/b...

-ari-

dOnlsM)

!irnj?[!nManuvi>mi anmiKvmflaufi

A

(b) BEJ.viin-3

(on)

i n W l l

©©

© nas b

a/ o a/

S)/b

5^aisijj<uwtiJ'u<uu)?!j'i^wei (effective list)<5s\j'uiJ<3j;n'ua-3Rjj

uaKis!Uue(T'?i?im^a'u<ri (pharmaceutical benefit

vmnrm

si. iTfyflaiwanuvi-Mnwu s)»l funn\JfuiJT['JiT«i4i«jJua!{iLni(5ii«tJ««] ay'I^

uas

en.

cn.cn

effectiveness)

(maximization of cost-

l!0m^

tfiflitf-iflffinifofoin

h^

to/to

(explicit information)

Si^n'W (evidence-based literature)sliiBwmtiuwaVilunnTnmaeniQiimjfniwfo

raia<^<

en.

'ih!j (compliance)

„•5K'u'u<Ll<3Sifsi''Uci'?ifnnpii ff]

Monitoring Program: SMP) 17UUW

n) iii-uyitmjqni ^ (©)

enr nrft WIVM

ws^w8ijlw'wwwnilu tmri finilau uasvujnai,viw (muusiln

m^inufnw

(Safety Monitoring Program: SMP)

(off-label indication)

(Safety

SMP

vim ffswu vfo

aL^

ff b I /• 0

sen c- y n, u

Q1°

s

y

n,

s

W L Q a ^

(u

«tf\w^

nri

Q/U3

(Drug Utilization Evaluation, DUE) IflLmaw

^) Imri9 (©,)

^

(n u PI(fej

(b)

•WJ41EJIV1W

:. EJI (k>)

ws

system)vi ?<wzria'i/'}zh"y''J?fw®

syi^

iltyl n

ua(authorized

(transparency) TflEJwniaumTufvniu-Bmim

afn a-ufk efovu watviticp

2?TO8fhtfty^4vmw*Bijftti>jn'rci ufUJPitmn

vifYWUfl

approach)(evidence-based

Siviwwa uautitnk^mi(evidence-based information)

is\j\jfl«uuu iSafEEMCI

evidence-based information

expertjudgement

iw

evidence-based medicine 38l)'MaivmjWllwitf\J\JfWJUtlU ISafE uasmju EMCI Iwuri

LnvtUiwa<iiiJlEJiumy\jmjEj'iau

ynwawvuuS^a^su?i9i QnSiiialininvi1aiviiivi£jjjmjEJik?iy'3

8&i4fi7\jriu

flJ «l

entnISafE aas EMCI

nsuuu ISafE ua« EMCI frrctta'rcnntwuirtrnj

ISafE tias EMCI 08l*l«1'J$ntiuwWJ

(social perspective)

cost-effectiveness analysis

(affordability)

(equity) ijnn

/•»

am Bft8iiwii&wci,uuw& WLiU'HiiuBKLflfefbfiLniwutLurtttufissnjy.

iuiytnvianuv-j<9n«cim)i

?s\ju\Jii«m4^snjj ^s

mvruwn

(effective list)

(pharmaceutical benefit scheme)

en/

n.

f\. isA F)

FI.

f l CJ ^ o/ i c. o / 9 /

^

A.

B.

c.

D. wiJQ£iSfiii Vi1sI'3R'M'Mi3jtTOit<u<unj?a£Ji-3 i|15fu (absolute contraindication)

(contraindicated/serious/major drug interaction) Yl

E.

F.

m^

iwwaA.

B.

A©

nT5^H£JTuanijqj?tnvisnii,vi-3 iP) luna'jj ACEI

enalapril (n)"

m^wl«8i«nuQnmy?£nvtahuwfln« lunau coxibsibuprofen (n)"

gastro protective agent IIJJQEJ tliu omeprazole (n)

W'Wnfi lunau coxibs WnuGI event

Health Technology Assessment (Chen

coxibs ym'U'UflMflami'vm 'wfieifi'u (QALY loss)

ibuprofen + generic omeprazole

'Jwanminfi Gl event

coxibs 5 excess risk

baseline risk(BNF ben) vtinypmui'i coxibs

prothrombotic agent S-aan^vhlwnfl myocardial

infarction Vila stroke

jj coxibs u

ezetimibe,rosuvastatin

lluri simvastatin (n) tmti/Vila atorvastatin (sto m§)

(Department of Defense Pharmacoeconomic

Center. MTF Formulary Management for Antilipidemic I Drugs

(Statins and Adjuncts), bood)

gliptins

l$u,ri metformin (n) uas sulfonylurea wt! glipizide (n) Vila

repaglinide (-0 lu$lb{JVIlllS sulfonamides uai! a-glucosidase

inhibitors \mn acarbose (PI) lias pioglitazone (-3)

C©

H n n a TU n <3 n u ft oi s n ^ sj m i

wn

(pnstnoEn dacarbazine) uatMiaaimi

. I-] I

Imiri

reimbursable indication

foash^m rituximab tuwba diffuse large-B-cell

lymphoma)

Cki nuwmUTlUiij coxibs, saw palmetto extract, omega-en

capsule 8nvitnBffl«tn) IvTl-o

NSAIDs

coxibs vilaH GC-©-adrenergic antagonists

saw palmetto extract uasK statins vtla fibrates

omega-en capsule

C«n

serratiopeptidase)

jJJ anti-inflammatory enzymes ( I "0

(wu acetylcysteine) In

Car

cinnarizine Lisa flunarizine flhunTvflSfi parkinsonism

cisapride on^flhunlviinw QT prolongation tiaaCi drug

interaction

fenoverine tlvinPl rhabdomyolysis

muscle relaxants t'rf'U orphenadrine

jfnvtfuyg^entjwnjj Beers Criteria boeilo

nimesulide tfniKlvflflfl fatal hepatotoxicity

short acting calcium channel blockers

nifedipine/diltiazem Wfl immediate release)

Iwuri

gatifloxacin

tegaserod

valdecoxib

rofecoxib

rosiglitazone

Cb

in Imiri

Vila cost-utility

cost-benefit Vila cost-effective

incremental cost

ml/a!

effectiveness ratio (ICER) ehm'i © iviTua^ GDP

u @>teo,ooo tnvipia QALY gain

vila <ooo flaasn? eia QALY gain)

rmK bisphosphonatelufmita-an'Ufns^nyinsnnl™ osteoporosis(primary prevention)

QALY gain s>.mte aTUtnvi ua^

QALY gain vi ®.deo) uefutnvi

il^ultlisnil f

coxibs i^EJunn NSAIDS(ibuprofen Vila diclofenac

my? n.) win'n UfliW 'njJWQ QALY gain efaCi celecoxib (low

dose) £tirf,s:oo; celecoxib (high dose) £sxts),ooo; etoricoxib

£en©,Gnoo; meloxicam (low dose) £©o,moo; meloxicam (high

dose) £s)CT/,doo www.hta.acuk/fullmono/mongilsg)g).pdf ^<3

nei'mU'ii celecoxib nn etoricoxib fl'i ijmnajfliiflilwI'LW

etia-3^Rjja^nf)'w (fWTWtnwwwlflifHiwfrJTJj whvi £cno,ooo

eia Q ALY gain) iias«nsi€ jj'nAwin coxibs vi

• rmW PPI ueniJfyflEJnvJanuvl inw wu esomeprazole (loo

vila s:o mg) lumifntnlifl GERD •dI V

QALM (quality-adjusted life

month) ujawtiiimjnflumDu (s^s: m) vl^ PPIVia Hb receptor antagonist

PI a QALM gain (Spiegel BM. lso®o)

' QALY gain

ntu is

q (=il QALM gain O.OGT/S)

esomeprazole uiu sr ailpnv •Blt i thsi l f l GERD

to TU/

unvi (

D.

snviei'n uw -atci w aii n-«a 3J\ tnl

(absolute contraindication)

(contra-

indicated/serious/major drug

interaction)

(absolute

contraindication)

n i uft fl vi n n VI -a Em

(contra-indicated/serious/

major drug inter-action) vunticva

(contraindicated) Vila

n n K s \ i i LI) u ati w-5 fil a) n vi fl w s 1 3 EJ

(serious) Vila

(major)

D® fovhuH fn lllu absolute contraindication

contraindication Vila precaution

relative

Dk>

Summary of Product Characteristics (5PC), US FDA official drug

labeling, Micromedex, Lexicomp, Clinical Pharmacology Vila

British National Formulary

E.

voran

course "ya-afmintnvnnol'u

voriconazole

nu fl-anPiifinnTi liposomal

amphotericin B

®o ivin

E©voriconazole

liposomal amphotericin B

US eX tu

Em

(http://apps.who.int/medicinedocs/pdf/h6nos)sie/h mosKae.pdf)

F.